Clinical trial: Three more volunteers given Oxford Covid-19 vaccine

Three more volunteers were administered the Oxford Covid-19 vaccine candidate at a medical college in Pune as part of the phase II clinical trial of the medicine

Coronavirus, vaccine, covid
Press Trust of India Pune
3 min read Last Updated : Aug 27 2020 | 3:23 PM IST

Three more volunteers were administered the Oxford COVID-19 vaccine candidate at a medical college in Pune on Thursday as part of the phase II clinical trial of the medicine, a senior doctor from the medical facility said.

Earlier, two volunteers, aged 32 and 48, were given a shot of the 'Covishied vaccine, being manufactured by the city-based Serum Institute of India (SII), on Wednesday when the phase II clinical trial of the medicine began at Bharti Vidyapeeth's Medical College and Hospital here.

"On Thursday afternoon, three more volunteers - two females and a male - were administered the vaccine candidate after their reports of RT-PCR test for COVID-19 and antibody test came negative," said Dr Sunita Palkar, in-charge of the research cell at the medical college.

She said following the administration of the vaccine dose to two volunteers on Wednesday, five more persons were screened. Out of them, the COVID-19 and antibody test reports of four came out negative on Thursday and they became eligible for the clinical trial.

The fifth volunteer was excluded from the trial as the person's antibody test report came out positive, she said.

The city-based KEM Hospital, another facility chosen for the vaccine's clinical trials in the country, is also scheduled to conduct a trial on some persons on Thursday, a senior doctor from the medical facility said.

"We screened five people yesterday and we are now waiting for their reports. As per the results of the report, thevaccine will be injected to the eligible volunteers," said the doctor.

Meanwhile, the vital health parameters of the two volunteers, who were administered the Oxford COVID-19 vaccine candidate at Bharti Vidyapeeth's Medical College and Hospital on Wednesday, are normal, the medical facility's deputy medical director Dr Jitendra Oswal said.

"Since yesterday, our medical team is in touch with the two volunteers and both are fine. They do not have any pain, fever, injection-side reaction or systemic illness post-vaccination," he said.

"They have been given all the necessary emergency numbers (to contact in case of need) and our medical team is also conducting follow-ups with them," he added.

The vaccine dose will be repeated on both the volunteers after one month, the hospital's medical director Dr Sanjay Lalwani earlier said.

He said in all, 25 candidates will be given the vaccine in the next seven days.

SII, the world's largest vaccine maker has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineOxford University

First Published: Aug 27 2020 | 3:20 PM IST

Next Story